​​HIV Functional Cure Momentum Builds as American Gene Technologies Approaches Data Readout

Collage of photos of AGT employees, scientists in the lab, and the AGT office building
Published on :

After achieving several important clinical milestones, momentum and excitement has been building for months around the company’s lead pipeline candidate AGT103-T, which is a potential HIV functional cure. In the coming months, the company expects to have the latest data readout for its Phase I trial. AGT103-T is a single-dose HIV gene therapy that could potentially replace antiretroviral therapy (ART) with a functional cure.

Maryland Life Science Companies Share Hopes for Annual BIO Convention

Published on :

Over a period of four days, life sciences companies from across the globe will descend on San Diego for the annual Biotechnology Innovation Organization (BIO) meeting. Multiple companies from Maryland, as well as the Department of Commerce, will be among them, showcasing the strength of the BioHealth Capital Region.

The Evolving Hunt for an HIV Cure, and How Gene Therapy is Paving the Way

Published on :

Today, a host of life sciences companies are utilizing gene therapy as a tool to find a cure for HIV. When discussing an HIV cure, there are two different possible targets: a “functional cure” where HIV is not eradicated but rather totally controlled without further ART treatment and a “sterilizing cure” that eliminates HIV completely from the body. 

Five Philly Gene Therapy Companies You Should Know

Published on :

More than 40 cell and gene therapy companies call Philadelphia home. Their work is facilitated by academic/industrial partnerships with world-class scientists at Children’s Hospital of Philadelphia (CHOP), Temple University, Drexel University, and University of Pennsylvania. Led by Wilson, UPenn’s Gene Therapy Program has been a particularly strong catalyst of the growth that led to $3 billion in investment in cell and gene therapies (CGT) in 2021. 

Despite Strong 2021 Performance Headwinds Remain for Biosimilars Uptake

Published on :

Biosimilars, also known as follow-on biologics, continued to capture greater market share and foment stronger competition with reference or brand name drugs in 2021. Increasing the number of biosimilars in the market and amplifying uptake by payers, family medical practices and pharmacies could be a gamechanger for patients and a healthcare system trying to reduce the cost of life-changing medicines.

Ellume Celebrates Grand Opening of First American Facility in Frederick, MD

Photo of Ellume's facility in Frederick, MD
Published on :

Governor Larry Hogan joined dozens of attendees at Ellume’s grand opening in Frederick on March 31 to welcome the diagnostics manufacturer to Frederick County. Ellume’s 215,000-square-foot production facility on Executive Way has been up and running since February 2022, only ten months after the company signed a lease with Matan Properties. 

Are Life Sciences Companies Going To Be Late To The Blockchain/Digital Assets Party?

Published on :

As of this week, there’s been heavy reporting that the Biden Administration has prepared new guidance on digital assets that could be released at any moment. Most of these reports suggest that the guidance will be centered around directing government agencies to study the potential benefits of Central Bank Digital Currencies (CBDCs), or tokenized versions of the US Dollar ($USD). These CBDCs have the capability to be minted on-demand and are programmable based on monetary policy set by the Federal Reserve and other entities. There’s other uses when paired with other digital assets that have the potential to improve and modernize the global financial system. 

Secretary of Commerce tours new I-270 Innovation Labs, flexible lab space meeting critical industry need

Published on :

From left to right: Kelly Shultz – Secretary of Commerce, State of Maryland; Luis Rugeles – Co-founder & CEO, I-270 Innovation Labs; and Doug Bane – Co-founder & COO, I-270 Innovation Labs.

Biotech Careers: Everyone Can Take Part in Shaping the Future

Maryland has built “one of the nation’s strongest life sciences industries”.
Published on :

The growing life sciences ecosystem in Maryland has become a shining star in the BioHealth Capital Region. The region has seen explosive growth driven by billions of federal dollars aimed at R&D efforts to combat the COVID-19 threat. And that continued growth has become a magnet for a robust supply of life sciences talent that will continue to shape the future of the state and region.